Loading…
Employees: 905
Size Standard Engineering Technology (SETL.NS) is an India Health Care company (Medical Specialties) with a market value of $796M, the 672nd largest of 1,058 India companies the cockpit tracks. Shares closed at ₹376.95 on 6 Nov 2026.
Performance Over six months the shares gained 163.6%, against -10.0% for the median peer and 0.0% for the India market (cap-weighted) — 2nd highest of 21 in its peer set.
Growth Revenue grew 26.1% over the last twelve months (peer median +9.1%); the operating margin is 13.2% (peer median 9.6%).
Valuation It trades at 8.9× enterprise value to sales against a peer median of 3.1× (3rd most expensive of 21).
Capital Return on invested capital runs 9.5 points below its cost of capital (20.0% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹8.49B | ₹7.74B | ₹6.14B | ₹5.44B | ₹4.98B |
| Revenue growth | — | +26% | +13% | +9% | — |
| Gross profit | ₹2.23B | ₹1.49B | ₹1.27B | ₹1.08B | ₹968M |
| EBITDA | ₹1.29B | ₹1.21B | ₹1.09B | ₹963M | ₹861M |
| Net income | ₹855M | ₹800M | ₹643M | ₹584M | ₹534M |
| Free cash flow | n/a | -₹54.7M | -₹265M | -₹1.07B | -₹340M |
| Capital expenditure | n/a | ₹615M | ₹278M | ₹336M | ₹294M |
| Total debt | n/a | ₹807M | ₹658M | ₹1.27B | ₹780M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | SETL.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -12.3% | -2.5% | 4th lowest of 21 |
| 6-month return | +163.6% | -10.0% | 2nd highest of 21 |
| Distance from 52-week high | -19.5% | -30.2% | 7th highest of 21 |
| Revenue growth (TTM) | +26.1% | +9.1% | 7th highest of 21 |
| Operating margin | 13.2% | 9.6% | 8th highest of 21 |
| EV / Sales | 8.9× | 3.1× | 3rd most expensive of 21 |
| ROIC minus cost of capital | -9.5 pp | +0.8 pp | 5th lowest of 21 |
| EV / EBITDA | 58.3× | 13.2× | most expensive of 8 |
| Net debt / EBITDA | -1.2× | 0.2× | 4th least indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Standard Engineering Technology SETL.NS | India | $796M | +164% | +26% | 13% | 8.9× | n/a | n/a |
| Cofoe Medical Technology 1187.HK | Hong Kong | $798M | -27% | +40% | 10% | 0.9× | -8.0% | +6.6% |
| Allmed Medical Products 002950.SZ | China | $798M | -39% | +14% | 8% | 1.6× | n/a | n/a |
| Shanghai Aladdin Biochemical Technology 688179.SS | China | $806M | -25% | +39% | 26% | 6.8× | 21.1% | +24.2% |
| Shanghai INT Medical Instruments 1501.HK | Hong Kong | $784M | -25% | +35% | 21% | 4.1× | -2.1% | +23.5% |
| Varex Imaging VREX | United States | $783M | -10% | +5% | 8% | 1.2× | n/a | n/a |
| BMC Medical 301367.SZ | China | $780M | -13% | +37% | 17% | 2.0× | 0.1% | +15.6% |
| Maccura Biotechnology 300463.SZ | China | $814M | -14% | -1% | -4% | 2.5× | 9.2% | -10.2% |
| Advanced Medical Solutions AMS.L | United Kingdom | $824M | +14% | +6% | 12% | 2.9× | 19.6% | +21.4% |
| Hangzhou Biotest Biotech 688767.SS | China | $824M | +5% | -4% | 3% | 9.7× | n/a | n/a |
| InMode INMD | United States | $767M | -5% | -7% | 18% | 0.7× | -10.5% | +12.4% |
| OrthoPediatrics KIDS | United States | $829M | +78% | +16% | -8% | 3.4× | n/a | n/a |
| Beijing Aerospace Changfeng 600855.SS | China | $832M | -35% | -10% | -19% | 5.1× | n/a | n/a |
| Cytek Biosciences CTKB | United States | $758M | +26% | +5% | -22% | 2.6× | n/a | n/a |
| Doctorglasses Chain 300622.SZ | China | $757M | -10% | +6% | 14% | 3.3× | -2.4% | +15.7% |
| Anhui Hongyu Wuzhou Medical Manufacturer 301234.SZ | China | $750M | +177% | -14% | 3% | 11.1× | 33.5% | -0.6% |
| Shenzhen Lifotronic Technology 688389.SS | China | $749M | -11% | +14% | 13% | 3.3× | 13.5% | +13.3% |
| Zylox-Tonbridge Medical Technology 2190.HK | Hong Kong | $851M | -13% | +39% | 25% | 4.0× | 5.5% | +105.8% |
| Beta Bionics BBNX | United States | $854M | +63% | +44% | -73% | 4.9× | n/a | n/a |
| Menicon 7780.T | Japan | $854M | +12% | +5% | 9% | 1.4× | n/a | n/a |
| Jiang Xi Sanxin Medtec 300453.SZ | China | $741M | -5% | +12% | 18% | 2.8× | -2.1% | +11.8% |